DTI-015 produces cures in T9 gliosarcoma

Neoplasia

Volumn 5, Issue 1, 2003, Pages 17-22

  Pietronigro, Dennis ^a,b   Drnovsky, Frank ^a   Cravioto, Humberto ^a   Ransohoff, Joseph ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Direct Therapeutics Inc   (United States)

Author keywords

DTI 015; Intratumoral; Malignant glioma; Stereotactic injection; T9 gliosarcoma

Indexed keywords

ALCOHOL; CARMUSTINE; DTI 015; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; GLIOSARCOMA; HISTOPATHOLOGY; INTRACRANIAL TUMOR; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SURVIVAL TIME;

EID: 0037250428     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1476-5586(03)80013-1     Document Type: Article

References (35)

1. Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, and Oldfield EH (1994). Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci USA 91, 2076-80.
2. 7-(2-hydroxyethyl)guanine as a molecular dosimeter of drug delivery to human brain tumors. Neurooncology 3, 241-45.
3. Brem H, Mahaley MS Jr., Vick NA, Black KL, Schold SC Jr., Burger PC, Friedman AH, Ciric IS, Eller TW, Cozzens JW, and Kenealy JN (1991). Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J Neurosurg 74, 441-46.
4. Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, Black K, Sisti M, Brem S, Mohr G, Muller P, Morawetz R, and Schold SC (1995). Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-Brain Tumor Treatment Group [see comments]. Lancet 345, 1008-12.
5. Carter J, Singh S, Leipold M, and Pietronigro D (2002). Increased antitumor efficacy of cisplatinum and 4-hydroperoxycyclophosphamide by solvent-facilitated perfusion. Proc Am Assoc Cancer Res, A381.
6. Cohen AR, Pietronigro DD, Cravioto H, and Flamm ES (1986). Effect of difluoromethylornithine on the antiglioma therapeutic efficacy of intraarterial BCNU. J Neurosurg 65, 671-78.
7. Dorr R, and Hoff DV (1994). Carmustine. In Cancer Chemotherapy Handbook. R Dorr and DV Hoff (Eds). Appleton and Lange, Norwalk. pp. 267-275.
8. Hasleton PS, O'Driscoll BR, Lynch P, Webster A, Kalra SJ, Gattamaneini HR, Woodcock AA, and Poulter LW (1991). Late BCNU lung: a light and ultrastructural study on the delayed effect of BCNU on the lung parenchyma. J Pathol 164, 31-36.
9. Hassenbusch SJ, Nardone EM, Levin VA, Leeds N, and Pietronigro D (2003). Stereotactic injection of DTI-015 into recurrent malignant gliomas: phase I/II trial. Neoplasia 5, 9-16.
10. Hassenbusch S, Levin V, Sawaya R, and Pietronigro D (2000). Intratumoral DTI-015 for inoperable recurrent malignant gliomas. Neurooncology 2, A93.
11. Hassenbusch S, Levin V, Smith D, Phuphanich S, Chen T, Chamberlain M, Cozzens J, Paleologos N, Hariharan S, Zappulla R, and Pietronigro D (2002). Multi-center Phase I/II trial of stereotactic injection of DTI-015 into inoperable recurrent malignant gliomas. In American Association of Neurological Surgeons, Brain Tumor Satellite Symposium, A20.
12. Hassenbusch S, Levin VA, and Bodell WJ (2001). DTI-015 in human glioma: evidence for a large treatment volume by analysis of DNA adduct formation. In Congress of Neurological Surgeons Poster Program Book, A189.
13. Hassenbusch SJ, Anderson JH, and Colvin OM (1996). Predicted and actual BCNU concentrations in normal rabbit brain during intraarterial and intravenous infusions. J Neurooncol 30, 7-18.
14. Hassenbusch SJ, Anderson JH, and Whiting DM (1990). Intra-arterial chemotherapy for brain tumors. Clevel Clin J Med 57, 513-20.
15. Jones RB, Matthes SM, Dufton C, Shpall E, Bearman S, Ross M, and Cagnoni P (1998). Nitrosoureas. In Clinician's Guide to Chemotherapy Pharmacokinetics and Pharmacodynamics. LB Grochow, and Ames MM (Eds). Williams and Wilkins, Baltimore, MD. pp. 331-44.
16. Kornblith PL, Smith BH, and Leonard LA (1981). Response of cultured human brain tumors to nitrosoureas: correlation with clinical data. Cancer 47, 255-65.
17. Kornblith PL, and Szypko PE (1978). Variations in response of human brain tumors to BCNU in vitro. J Neurosurg 48, 580-86.
18. Kupersmith MJ, Frohman LP, Choi IS, S HF, Hiesinger E, Berenstein A, Wise A, Carr RE, and Ransohoff J (1988). Visual system toxicity following intra-arterial chemotherapy. Neurology 38, 284-89.
19. Laske DW, Youle RJ, and Oldfield EH (1997). Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med 3, 1362-68.
20. Miller DF, Bay JW, Lederman RJ, Purvis JD, Rogers LR, and Tomsak RT (1985). Ocular and orbital toxicity following intracarotid injection of BCNU (carmustine) and cisplatinum for malignant gliomas. Ophthalmology 92, 402-406.
21. Morrison PF, Laske DW, Bobo H, Oldfield EH, and Dedrick RL (1994). High-flow microinfusion: tissue penetration and pharmacodynamics. Am J Physiol 266, R292-305.
22. Nagahiro S, Yamamoto YL, Diksic M, Mitsuka S, Sugimoto S, and Feindel W (1991). Neurotoxicity after intracarotid 1,3-bis(2-chloroethyl)-1-nitrosourea administration in the rat: hemodynamic changes studied by double-tracer autoradiography. Neurosurgery 29, 19-25 discussion, p. 26.
23. O'Driscoll BR, Hasleton PS, Taylor PM, Poulter LW, Gattamaneni HR, and Woodcock AA (1990). Active lung fibrosis up to 17 years after chemotherapy with carmustine (BCNU) in childhood. N Engl J Med 323, 378-82.
24. Omojola MF, Fox AJ, Auer RN, and Vinuela FV (1982). Hemorrhagic encephalitis produced by selective non-occlusive intracarotid BCNU injection in dogs. J Neurosurg 57, 791-96.
25. Pietronigro D, Drnovsky F, Cravioto H, and Ransohoff J (1999). Stereotactic intratumoral injection of DTI-015 in a rat intracranial T9 gliosarcoma model. Proc Am Assoc Cancer Res 40, 583.
26. 14C-BCNU concentrations following intratumoral injection of DTI-015 in rat 9L brain tumors. Proc Am Assoc Cancer Res 41, 523.
27. Roh M, Charnsangavej C, Fornage B, and Pietronigro D (1998). Intratumoral injection of DTI-136 for inoperable liver tumors. Proc Am Soc Clin Oncol 17, A692.
28. Rosenblum MK, Delattre J-Y, Walker RW, and Shapiro W (1989). Fatal necrotizing encephalopathy complicating treatment of malignant gliomas with intra-arterial BCNU and irradiation: a pathological study. J Neurooncol 7, 269-81.
29. Ross BD, Frey K, Desmond T, and Pietronigro D (2002). Rapid and selective tumor distribution of DTI-015. In American Association of Neurological Surgeons, Brain Tumor Satellite Symposium, A60.
30. Shapiro WR, Green SB, Burger PC, Selker RG, VanGilder JC, Robertson JT, and Mahaley MS (1992). A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma. J Neurosurg 76, 772-81.
31. Shiina S, Tagawa K, Unuma T, and Terano A (1990). Percutaneous ethanol injection therapy for the treatment of hepatocellular carcinoma. Am J Roentgenol 154, 947-51.
32. Simpson-Herren L, and Pietronigro D (1999). Intratumoral injection of DTI-015 in the Walker 256 subcutaneous model. Proc Am Assoc Cancer Res 40, 583.
33. Thompson GR, and Larson RE (1969). The hepatotoxicity of 1,3-bis (2-chloroethyl)-1-nitrosurea (BCNU) in rats. J Pharmacol Exp Ther 166, 104-12.
34. Thompson GR,and Larson RE (1972). A toxicologic comparison of the potency and activity of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in mice and rats. Toxicol Appl Pharmacol 21, 405-13.
35. Walker MD, Green SB, Byar DP, Alexander E, Batzdorf U, Brooks WH, Hunt WE, MacCarty CS, Mahaley MS, Mealey J, Owens G, Ransohoff J, Robertson JT, Shapiro WR, Smith KR, Wilson CB, and Strike TA (1980). Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 303, 1323-29.